Skip to main content

Advertisement

SpringerLink
Log in

Non-interferon Therapies for Hepatitis C

  • Hepatitis C: Therapeutics (E Lawitz and M Manns, Section Editors)
  • Published:
Current Hepatitis Reports Aims and scope Submit manuscript

Abstract

Hepatitis C (HCV) therapy is currently undergoing a revolution with the development of new classes of Direct Acting Antivirals (DAAs) with distinct mechanisms of action, potency, resistance patterns and significantly less side effects compared to current standard of care therapies. Our patients have struggled with interferon based therapies for the last 2 decades, but now we are at a turning point with the development of new non-interferon combinations of DAAs. These new molecules have demonstrated to be effective, safe and most importantly have shown the capacity to achieve a sustained virological response in the absence of interferon. This article summarizes the available published clinical trials that are rapidly contributing to our understanding of how we might need to combine these new antivirals to achieve the highest rates of cure in HCV patients who are treatment naïve, non-responders or cirrhotic, across all genotypes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ciesek S, von Hahn T, Manns MP. Second-wave protease inhibitors: choosing an heir. Clin Liver Dis. 2011;15(3):597–609.

    Google Scholar 

  2. Gish RG, Meanwell NA. The NS5A replication complex inhibitors: difference makers? Clin Liver Dis. 2011;15(3):627–39.

    Google Scholar 

  3. Membreno FE, Lawitz EJ. The HCV NS5B nucleoside and non-nucleoside inhibitors. Clin Liver Dis. 2011;15(3):611–26.

    Google Scholar 

  4. Ilyas JA, Vierling JM. An overview of emerging therapies for the treatment of chronic hepatitis C. Clin Liver Dis. 2011;15(3):515–36.

    Google Scholar 

  5. • Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2010;376(9751):1467–75. This 14 day study showed for the first time that a non-interferon combination of DAAs was capable of profound viral suppression in both naïve and null non-responders HCV patients.

  6. •• Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366(3):216–24. This is the first US proof of concept study that demonstrated that a combination of DAAs can achieve a HCV cure without the use of interferon.

  7. Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 2012;55(3):742–8.

    Google Scholar 

  8. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360(18):1839–50.

    Article  PubMed  CAS  Google Scholar 

  9. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195–206.

    Google Scholar 

  10. Zeuzem S, Buggisch P, Agarwal K, et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology. 2011;55(3):749–58.

    Google Scholar 

  11. Vertex announces 12-week on-treatment data and SVR4 from Phase 2 Study of interferon-free (all-oral) treatment regimen of INCIVEK®, VX-222 and ribavirin in people with genotype 1 hepatitis C.; Available at: http://investors.vrtx.com/releases.cfm?hdr02=press. Accessed March 2012.

  12. Zeuzem S, Asselah T, Angus P, et al. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology. 2011;141(6):2047–55; quiz e2014.

    Google Scholar 

  13. Zeuzem S, Asselah T, Angus P, et al. High sustained virologic response following interferon-free treatment of chronic HCV GT1 infection for 4 weeks with HCV protease inhibitor BI201335, polymerase inhibitor BI207127 and ribavirin, followed by BI201335 and PEGIFN/Ribavirin—the Sound-C1 Study. Presented at AASLD Conference. San Francisco, CA. November 4–8, 2011. Abstract #249.

  14. Zeuzem S, Soriano V, Asselah T, et al. Virologic response to an interferon-free regimen of BI201335 and BI 207127, with and without ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: week 12 interim results of the Sound-=C2 study. Presented at AASLD Conference. San Francisco, CA. November 4–8, 2011. Abstract #LB15.

  15. •• Zeuzem S, Soriano V, Asselah T, et al. SVR4 and SVR12 with an interferon-free regimen of BI 201335 AND BI 207127, +/− ribavirin, in treatment-naïve patients with chronic genotype-1 HCV infection: Interim results of SOUND-C2. EASL 47th Annual Meeting, April 18th–22nd 2012, Barcelona, Spain. Abstract #101. This is the first study to demonstrate that it is possible to achieve a sustained virological response with an interferon-free combination of DAAs in patients with cirrhosis.

  16. Pawlotsky JM, Flisiak R, Rasenack J, et al. Once daily alisporivir interferon (IFN)-free regimens achieve high rates of early HCV clearance in previously untreated patients with HCV genotype (G) 2 or 3. Presented at AASLD Conference. San Francisco, CA. November 4–8, 2011. Abstract #LB-11.

  17. Pawlotsky JM, Sarin SK, Foster GR, et al. Alisporivir plus ribavirin is highly effective as interferon-free or interferon-add-on regimen in previously untreated HCV-G2 or G3 patients: SVR12 results from VITAL-1 Phase 2b study. EASL 47th Annual Meeting, April 18th–22nd 2012, Barcelona, Spain. Abstract #1405.

  18. Sulkowski MS, Rodriguez-Torres M, Lawitz E, et al. High sustained virologic response rates in treatment-naïve HCV genotype 1a and 1b patients treated for 12 or 24 weeks with an interferon-free all-oral quad regimen: interim results. EASL 47th Annual Meeting, April 18th–22nd 2012, Barcelona, Spain. Abstract #1421.

  19. Lawitz E, Poordad F, Kowdley K, et al. A 12-week interferon-free regimen of ABT-450/r, ABT-072, and ribavirin was well tolerated and achieved sustained virologic response in 91 % treatment-naïve HCV IL28B-CC genotype-1-infected subjects. EASL 47th Annual Meeting, April 18th–22nd 2012, Barcelona, Spain. Abstract #13.

  20. Lawitz E, Poordad F, Krowdley K, et al. 12-Week interferon-free regimen of ABT-450/r+ABT-333+Ribavirin achieved SVR12 in up to 95 % of treatment-naive HCV genotype-1-infected subjects with lower response rates in HCV genotype-1-infected previous non-responders. EASL 47th Annual Meeting, April 18th–22nd 2012, Barcelona, Spain. Abstract #1399.

  21. •• Sulkowski MS, Lawitz E, Hinestrosa F, et al. Potent viral suppression with all-oral combination therapy with daclatasvir (NS5A Inhibitor) and PSI-7977 (NS5B Inhibitor), +/− ribavirin, in treatment-naive patients with chronic HCV infection. Presented at EASL Conference. Barcelona, Spain. April 18–22, 2012.Poster #1422. This study demonstrated that the combination of a NS5A inhibitor and a NI for 24 weeks represent a potent non-interferon combination that achieved 100 % SVR4 in all patients with HCV genotype 1 even without RBV.

  22. Gane E, Stedman CA, Hyland R, et al. Once daily PSI-7977 plus RBV: pegylated interferon-alfa not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3. The 62nd Annual Meeting of the Association for the Study of Liver Diseases, November 4–8, 2012, San Francisco, CA. Abstract #34.

  23. Gane E, Stedman CA, Hyland R, et al. ELECTRON: once daily GS-7977 plus ribavirin in HCV GT 1/2/3. EASL 47th Annual Meeting, April 18th–22nd 2012, Barcelona, Spain. Abstract #1113.

  24. Gilead announces early sustained virologic response rates for GS-7977 plus ribavirin in genotype 1 treatment-naïve Hepatitis C patients. Available at: http://www.gilead.com/press_archive. Accessed on: April 2012.

Download references

Author information

Authors and Affiliations

  1. Alamo Medical Research, 621 Camden St, Suite 202, San Antonio, TX, 78215, USA

    Fernando E. Membreno & Eric J. Lawitz

Authors
  1. Fernando E. Membreno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric J. Lawitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric J. Lawitz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Membreno, F.E., Lawitz, E.J. Non-interferon Therapies for Hepatitis C. Curr Hepatitis Rep 11, 146–152 (2012). https://doi.org/10.1007/s11901-012-0133-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-012-0133-7

Keywords

Search

Navigation